Oxaliplatin - A 10-year trajectory

Shingo Kanaji, Eiji Oki, Hiroshi Saeki, Hiroyuki Kitao, Yoshihiko Maehara, Yoshihiro Kakeji

Research output: Contribution to journalReview article

Abstract

Oxaliplatin (Elplat® iv infusion solution) is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

Original languageEnglish
Pages (from-to)715-722
Number of pages8
JournalJapanese Journal of Cancer and Chemotherapy
Volume43
Issue number6
Publication statusPublished - Jun 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Oxaliplatin - A 10-year trajectory'. Together they form a unique fingerprint.

  • Cite this

    Kanaji, S., Oki, E., Saeki, H., Kitao, H., Maehara, Y., & Kakeji, Y. (2016). Oxaliplatin - A 10-year trajectory. Japanese Journal of Cancer and Chemotherapy, 43(6), 715-722.